Skip to content

Italian Lung Cancer Observational Study

Italian Lung Cancer Observational Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05851755
Acronym
LUCENT
Enrollment
1000
Registered
2023-05-10
Start date
2023-04-01
Completion date
2028-03-31
Last updated
2023-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer

Brief summary

LUCENT is an observational study focused on malignant pulmonary and tracheo-bronchial disease. It involves a large proportion of reference Italian thoracic surgery centers. The relevance of the study is related to the epidemiology of lung cancer in the world - also known as Big Killer - and the high mortality rates both in males and females. The aim of his prospective study is to collect a large bulk of postoperative patients' outcome data and to produce up-to-date descriptive statistics of patients undergoing surgery for lung cancer. These results will be pivotal to compare the clinical results of all the relevant specialities involved in the care of lung cancer such as medical oncologists and radiation oncologists.

Interventions

None listed

Sponsors

S. Andrea Hospital
CollaboratorOTHER
Azienda Policlinico Umberto I
CollaboratorOTHER
Azienda Ospedaliero, Universitaria Pisana
CollaboratorOTHER
Università degli Studi dell'Aquila
CollaboratorOTHER
University of Milan
CollaboratorOTHER
Azienda Ospedaliera di Perugia
CollaboratorOTHER
Monaldi Hospital
CollaboratorOTHER
Azienda Ospedaliera di Bolzano
CollaboratorOTHER
AUSL Romagna Rimini
CollaboratorOTHER
European Institute of Oncology
CollaboratorOTHER
Università degli Studi di Ferrara
CollaboratorOTHER
Azienda Socio Sanitaria Territoriale di Mantova
CollaboratorOTHER
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with lung cancer * informed consent

Exclusion criteria

* alcohol or drug abuse * age \< 18 * inability to express consent

Design outcomes

Primary

MeasureTime frameDescription
Lung cancer surgery outcomes5 yearsBenchmarking national outcome data of the treatment of lung cancer

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026